New data on risk of serious infections will help selection of biologics in RA

Rates of serious infections are generally similar for different biologic drugs used in RA, but small differences may be important when selecting therapy for high risk patients, an analysis of UK registry data concludes. Using etanercept as a reference, the rate of serious infections was slightly lower with certolizumab pegol (hazard ratio 0.75) and slightly ...

Already a member?

Login to keep reading.

© 2021 the limbic